Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04822181




Registration number
NCT04822181
Ethics application status
Date submitted
26/03/2021
Date registered
30/03/2021
Date last updated
31/10/2024

Titles & IDs
Public title
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
Scientific title
The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis
Secondary ID [1] 0 0
U1111-1244-3678
Secondary ID [2] 0 0
NN9931-4553
Universal Trial Number (UTN)
Trial acronym
ESSENCE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-alcoholic Steatohepatitis 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Metabolic and Endocrine 0 0 0 0
Metabolic disorders
Diet and Nutrition 0 0 0 0
Obesity

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Semaglutide
Treatment: Drugs - Placebo

Experimental: Semaglutide OW (once weekly ) - Semaglutide administrated subcutaneously once weekly

Placebo comparator: Placebo - Placebo administrated subcutaneously once weekly


Treatment: Drugs: Semaglutide
Semaglutide administrated subcutaneously (under the skin) once weekly there will be a period of dose escalation before reaching the target dose.

Treatment: Drugs: Placebo
Placebo administrated subcutaneously (under the skin) once weekly.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part 1: Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No)
Timepoint [1] 0 0
From randomisation (week 0) to week 72
Primary outcome [2] 0 0
Part 1: Improvement in liver fibrosis and no worsening of steatohepatitis (Yes/No)
Timepoint [2] 0 0
From randomisation (week 0) to week 72
Primary outcome [3] 0 0
Part 2: Cirrhosis-free survival (Yes/No)
Timepoint [3] 0 0
From randomisation (week 0) to week 240
Secondary outcome [1] 0 0
Change in body weight
Timepoint [1] 0 0
From randomisation (week 0) to week 72
Secondary outcome [2] 0 0
Resolution of steatohepatitis and improvement in liver fibrosis (Yes/No)
Timepoint [2] 0 0
From randomisation (week 0) to week 72
Secondary outcome [3] 0 0
Change in SF-36 (Short Form 36) Bodily Pain
Timepoint [3] 0 0
From randomisation (week 0) to week 72
Secondary outcome [4] 0 0
Change in body weight
Timepoint [4] 0 0
From randomisation (week 0) to week 240
Secondary outcome [5] 0 0
Improvement in steatohepatitis with at least a 2-point reduction in NAS and no worsening of fibrosis (Yes/No)
Timepoint [5] 0 0
From randomisation (week 0) to week 72
Secondary outcome [6] 0 0
Change in histology-assessed liver collagen proportionate area
Timepoint [6] 0 0
From randomisation (week 0) to week 72
Secondary outcome [7] 0 0
Worsening in steatohepatitis (Yes/No)
Timepoint [7] 0 0
From randomisation (week 0) to week 72
Secondary outcome [8] 0 0
Improvement in histology-assessed ballooning (Yes/No)
Timepoint [8] 0 0
From randomisation (week 0) to week 72
Secondary outcome [9] 0 0
Improvement in histology-assessed inflammation (Yes/No)
Timepoint [9] 0 0
From randomisation (week 0) to week 72
Secondary outcome [10] 0 0
Improvement in histology-assessed steatosis (Yes/No)
Timepoint [10] 0 0
From randomisation (week 0) to week 72
Secondary outcome [11] 0 0
NASH resolution (ballooning of 0, inflammation of 0-1) and above or equal to 2point NAS reduction with no worsening of fibrosis
Timepoint [11] 0 0
From randomisation (week 0) to week 72
Secondary outcome [12] 0 0
Progression of liver fibrosis in patients with F2 at baseline (Yes/No)
Timepoint [12] 0 0
From randomisation (week 0) to week 72
Secondary outcome [13] 0 0
Progression of liver fibrosis
Timepoint [13] 0 0
From randomisation (week 0) to week 72
Secondary outcome [14] 0 0
Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No)
Timepoint [14] 0 0
From randomisation (week 0) to week 240
Secondary outcome [15] 0 0
Improvement in liver fibrosis and no worsening of steatohepatitis (Yes/No)
Timepoint [15] 0 0
From randomisation (week 0) to week 240
Secondary outcome [16] 0 0
Changes in liver stiffness values assessed by transient elastography (FibroScan®)
Timepoint [16] 0 0
From randomisation (week 0) to week 72 and week 240
Secondary outcome [17] 0 0
Change in ELF (Enhanced Liver Fibrosis) score
Timepoint [17] 0 0
From randomisation (week 0) to week 72 and week 240
Secondary outcome [18] 0 0
Change in ALT (alanine aminotransferase)
Timepoint [18] 0 0
From randomisation (week 0) to week 72 and week 240
Secondary outcome [19] 0 0
Change in AST (aspartate aminotransferase)
Timepoint [19] 0 0
From randomisation (week 0) to week 72 and week 240
Secondary outcome [20] 0 0
Change in CAP (Controlled Attenuation Parameter) values assessed by transient elastography (FibroScan)
Timepoint [20] 0 0
From randomisation (week 0) to week 72 and week 240
Secondary outcome [21] 0 0
Change in FAST (FibroScan-AST) score
Timepoint [21] 0 0
From randomisation (week 0) to week 72 and week 240
Secondary outcome [22] 0 0
Change in Pro-C3 (pro-peptide of type III collagen)
Timepoint [22] 0 0
From randomisation (week 0) to week 72 and week 240
Secondary outcome [23] 0 0
Change in inflammation assessed by hsCRP (High Sensitive C-Reactive Protein)
Timepoint [23] 0 0
From randomisation (week 0) to week 72 and week 240
Secondary outcome [24] 0 0
Change in HbA1c (glycated haemoglobin)
Timepoint [24] 0 0
From randomisation (week 0) to week 72 and week 240
Secondary outcome [25] 0 0
Change in triglyceride
Timepoint [25] 0 0
From randomisation (week 0) to week 72 and week 240
Secondary outcome [26] 0 0
Change in free fatty acids
Timepoint [26] 0 0
From randomisation (week 0) to week 72 and week 240
Secondary outcome [27] 0 0
Change in LDL (low-density lipoprotein) cholesterol
Timepoint [27] 0 0
From randomisation (week 0) to week 72 and week 240
Secondary outcome [28] 0 0
Change in HDL (High density lipoprotein ) cholesterol
Timepoint [28] 0 0
From randomisation (week 0) to week 72 and week 240
Secondary outcome [29] 0 0
Time to first MACE(Major Adverse Cardiovascular event ) (composite endpoint)
Timepoint [29] 0 0
From randomisation (week 0) to week 240
Secondary outcome [30] 0 0
Major cardio-hepatic event-free survival (Yes/No)
Timepoint [30] 0 0
From randomisation (week 0) to week 240
Secondary outcome [31] 0 0
Changes in SF-36 (Short Form 36 v2.0 acute ) Physical Component Summary
Timepoint [31] 0 0
From randomisation (week 0) to week 72 and week 240
Secondary outcome [32] 0 0
Changes in SF-36 Mental Component Summary
Timepoint [32] 0 0
From randomisation (week 0) to week 72 and week 240
Secondary outcome [33] 0 0
Change in SF-36 Bodily Pain
Timepoint [33] 0 0
From randomisation (week 0) to week 240
Secondary outcome [34] 0 0
Changes in NASH-CHECK Abdominal Pain
Timepoint [34] 0 0
From randomisation (week 0) to week 72 and week 240

Eligibility
Key inclusion criteria
* Age above or equal to 18 years at the time of signing informed consent.
* Histological evidence of NASH based on a central pathologist evaluation of the baseline liver biopsy. The baseline liver biopsy can be a historical biopsy obtained within 180 days prior to the screening visit (V1).
* Histological evidence of fibrosis stage 2 or stage 3 according to the NASH CRN (Clinical Research Network) classification based on a central pathologist evaluation of the baseline liver biopsy.
* A histological NAS (Non-alcoholic fatty liver disease Activity Score) above or equal to 4 with a score of 1 or more in steatosis, lobular inflammation and hepatocyte ballooning based on a central pathologist evaluation of the baseline liver biopsy.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Documented causes of chronic liver disease other than non-alcoholic fatty liver disease (NAFLD)
* Positive HBsAg, positive anti-HIV, positive HCV RNA at screening (V2A) or any known presence of HCV RNA or HBsAg within 2 years of screening (V2A).
* Presence or history of ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis or liver transplantation at randomisation.
* Known or suspected excessive consumption of alcohol (greater than 20 g/day for women or greater than 30 g/day for men) or alcohol dependence (assessed by the Alcohol Use Disorders Identification Test (AUDIT questionnaire)).
* Treatment with vitamin E (at doses greater than or equal to 800 IU/day) or pioglitazone or medications approved for treatment of NASH which has not been at a stable dose in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, treatment should be at a stable dose from time of biopsy until screening.
* Treatment with GLP-1 RAs in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, any treatment with GLP-1 RAs from time of biopsy until screening (V2A).
* Treatment with glucose-lowering agent(s) (other than GLP-1 RAs), lipid-lowering medication or weight loss medication not stable in the opinion of the investigator in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, treatment should be at a stable dose in the opinion of the investigator from time of biopsy until screening.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
25/04/2029
Actual
Sample size
Target
1200
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
A.W. Morrow Gastroenterology and Liver Centre - Camperdown
Recruitment hospital [2] 0 0
Nepean Hospital - Kingswood
Recruitment hospital [3] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [4] 0 0
Westmead Hospital - Westmead
Recruitment hospital [5] 0 0
Griffith University Clinical Trial Unit - Southport
Recruitment hospital [6] 0 0
Royal Adelaide Hospital - Hepatology- 5E291 - Adelaide
Recruitment hospital [7] 0 0
Lyell McEwin Hospital - Elizabeth Vale
Recruitment hospital [8] 0 0
St Vincent's Hospital (Melbourne) - Fitzroy
Recruitment hospital [9] 0 0
Austin Health - Heidelberg
Recruitment hospital [10] 0 0
Fiona Stanley Hospital - Hepatology - Murdoch
Recruitment hospital [11] 0 0
Sir Charles Gairdner Hospital_Nedlands - Nedlands
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2747 - Kingswood
Recruitment postcode(s) [3] 0 0
2170 - Liverpool
Recruitment postcode(s) [4] 0 0
2145 - Westmead
Recruitment postcode(s) [5] 0 0
4222 - Southport
Recruitment postcode(s) [6] 0 0
5000 - Adelaide
Recruitment postcode(s) [7] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [8] 0 0
3065 - Fitzroy
Recruitment postcode(s) [9] 0 0
3084 - Heidelberg
Recruitment postcode(s) [10] 0 0
6150 - Murdoch
Recruitment postcode(s) [11] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Iowa
Country [12] 0 0
United States of America
State/province [12] 0 0
Kansas
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Maryland
Country [15] 0 0
United States of America
State/province [15] 0 0
Massachusetts
Country [16] 0 0
United States of America
State/province [16] 0 0
Michigan
Country [17] 0 0
United States of America
State/province [17] 0 0
Minnesota
Country [18] 0 0
United States of America
State/province [18] 0 0
Mississippi
Country [19] 0 0
United States of America
State/province [19] 0 0
Missouri
Country [20] 0 0
United States of America
State/province [20] 0 0
Nebraska
Country [21] 0 0
United States of America
State/province [21] 0 0
Nevada
Country [22] 0 0
United States of America
State/province [22] 0 0
New Jersey
Country [23] 0 0
United States of America
State/province [23] 0 0
New York
Country [24] 0 0
United States of America
State/province [24] 0 0
North Carolina
Country [25] 0 0
United States of America
State/province [25] 0 0
Ohio
Country [26] 0 0
United States of America
State/province [26] 0 0
Pennsylvania
Country [27] 0 0
United States of America
State/province [27] 0 0
Rhode Island
Country [28] 0 0
United States of America
State/province [28] 0 0
South Carolina
Country [29] 0 0
United States of America
State/province [29] 0 0
Tennessee
Country [30] 0 0
United States of America
State/province [30] 0 0
Texas
Country [31] 0 0
United States of America
State/province [31] 0 0
Utah
Country [32] 0 0
United States of America
State/province [32] 0 0
Virginia
Country [33] 0 0
Argentina
State/province [33] 0 0
Buenos Aires
Country [34] 0 0
Argentina
State/province [34] 0 0
Caba
Country [35] 0 0
Argentina
State/province [35] 0 0
Capital Federal
Country [36] 0 0
Argentina
State/province [36] 0 0
Florencio Varela, Buenos Aires
Country [37] 0 0
Austria
State/province [37] 0 0
Graz
Country [38] 0 0
Austria
State/province [38] 0 0
Saint Stefan
Country [39] 0 0
Austria
State/province [39] 0 0
Wien
Country [40] 0 0
Belgium
State/province [40] 0 0
Bruxelles
Country [41] 0 0
Belgium
State/province [41] 0 0
Edegem
Country [42] 0 0
Belgium
State/province [42] 0 0
Genk
Country [43] 0 0
Belgium
State/province [43] 0 0
Gent
Country [44] 0 0
Brazil
State/province [44] 0 0
Goias
Country [45] 0 0
Brazil
State/province [45] 0 0
Rio Grande Do Sul
Country [46] 0 0
Brazil
State/province [46] 0 0
Sao Paulo
Country [47] 0 0
Brazil
State/province [47] 0 0
São Paulo
Country [48] 0 0
Brazil
State/province [48] 0 0
Rio de Janeiro
Country [49] 0 0
Bulgaria
State/province [49] 0 0
Plovdiv
Country [50] 0 0
Bulgaria
State/province [50] 0 0
Sofia
Country [51] 0 0
Bulgaria
State/province [51] 0 0
Varna
Country [52] 0 0
Canada
State/province [52] 0 0
Alberta
Country [53] 0 0
Canada
State/province [53] 0 0
British Columbia
Country [54] 0 0
Canada
State/province [54] 0 0
Nova Scotia
Country [55] 0 0
Canada
State/province [55] 0 0
Ontario
Country [56] 0 0
Canada
State/province [56] 0 0
Quebec
Country [57] 0 0
China
State/province [57] 0 0
Beijing
Country [58] 0 0
China
State/province [58] 0 0
Chongqing
Country [59] 0 0
China
State/province [59] 0 0
Guangdong
Country [60] 0 0
China
State/province [60] 0 0
Hebei
Country [61] 0 0
China
State/province [61] 0 0
Hunan
Country [62] 0 0
China
State/province [62] 0 0
Jiangsu
Country [63] 0 0
China
State/province [63] 0 0
Jilin
Country [64] 0 0
China
State/province [64] 0 0
Ningxia
Country [65] 0 0
China
State/province [65] 0 0
Shandong
Country [66] 0 0
China
State/province [66] 0 0
Shanghai
Country [67] 0 0
China
State/province [67] 0 0
Sichuan
Country [68] 0 0
China
State/province [68] 0 0
Tianjin
Country [69] 0 0
China
State/province [69] 0 0
Zhejiang
Country [70] 0 0
China
State/province [70] 0 0
Guangzhou
Country [71] 0 0
China
State/province [71] 0 0
Hangzhou
Country [72] 0 0
China
State/province [72] 0 0
Nanchang
Country [73] 0 0
China
State/province [73] 0 0
Shenzhen
Country [74] 0 0
Croatia
State/province [74] 0 0
Osijek
Country [75] 0 0
Croatia
State/province [75] 0 0
Rijeka
Country [76] 0 0
Croatia
State/province [76] 0 0
Split
Country [77] 0 0
Croatia
State/province [77] 0 0
Zagreb
Country [78] 0 0
Czechia
State/province [78] 0 0
Liberec
Country [79] 0 0
Czechia
State/province [79] 0 0
Plzen
Country [80] 0 0
Czechia
State/province [80] 0 0
Prague 2
Country [81] 0 0
Denmark
State/province [81] 0 0
Aarhus N
Country [82] 0 0
Denmark
State/province [82] 0 0
Hvidovre
Country [83] 0 0
Denmark
State/province [83] 0 0
København NV
Country [84] 0 0
Denmark
State/province [84] 0 0
Odense C
Country [85] 0 0
France
State/province [85] 0 0
Angers
Country [86] 0 0
France
State/province [86] 0 0
Clichy
Country [87] 0 0
France
State/province [87] 0 0
Lille
Country [88] 0 0
France
State/province [88] 0 0
Nice
Country [89] 0 0
France
State/province [89] 0 0
Paris
Country [90] 0 0
Germany
State/province [90] 0 0
Leipzig
Country [91] 0 0
Germany
State/province [91] 0 0
Lübeck
Country [92] 0 0
Germany
State/province [92] 0 0
Mainz
Country [93] 0 0
Greece
State/province [93] 0 0
Athens
Country [94] 0 0
Greece
State/province [94] 0 0
Goudi, Athens
Country [95] 0 0
Greece
State/province [95] 0 0
Ioannina
Country [96] 0 0
Greece
State/province [96] 0 0
Thessaloniki
Country [97] 0 0
India
State/province [97] 0 0
Andhra Pradesh
Country [98] 0 0
India
State/province [98] 0 0
Gujarat
Country [99] 0 0
India
State/province [99] 0 0
Haryana
Country [100] 0 0
India
State/province [100] 0 0
Karnataka
Country [101] 0 0
India
State/province [101] 0 0
Maharashtra
Country [102] 0 0
India
State/province [102] 0 0
New Delhi
Country [103] 0 0
India
State/province [103] 0 0
Punjab
Country [104] 0 0
India
State/province [104] 0 0
Rajasthan
Country [105] 0 0
India
State/province [105] 0 0
Telangana
Country [106] 0 0
Ireland
State/province [106] 0 0
Dublin
Country [107] 0 0
Israel
State/province [107] 0 0
Haifa
Country [108] 0 0
Israel
State/province [108] 0 0
Jerusalem
Country [109] 0 0
Israel
State/province [109] 0 0
Petah-Tikva
Country [110] 0 0
Israel
State/province [110] 0 0
Ramat-Gan
Country [111] 0 0
Israel
State/province [111] 0 0
Tel Aviv
Country [112] 0 0
Italy
State/province [112] 0 0
Cz
Country [113] 0 0
Italy
State/province [113] 0 0
Foggia
Country [114] 0 0
Italy
State/province [114] 0 0
Bologna
Country [115] 0 0
Italy
State/province [115] 0 0
Firenze
Country [116] 0 0
Italy
State/province [116] 0 0
Milano
Country [117] 0 0
Italy
State/province [117] 0 0
Palermo
Country [118] 0 0
Italy
State/province [118] 0 0
Roma
Country [119] 0 0
Italy
State/province [119] 0 0
Rome
Country [120] 0 0
Italy
State/province [120] 0 0
Torino
Country [121] 0 0
Japan
State/province [121] 0 0
Bunkyo-ku, Tokyo
Country [122] 0 0
Japan
State/province [122] 0 0
Fukui-shi, Fukui
Country [123] 0 0
Japan
State/province [123] 0 0
Fukushima
Country [124] 0 0
Japan
State/province [124] 0 0
Gifu
Country [125] 0 0
Japan
State/province [125] 0 0
Hamamatsu-shi, Shizuoka
Country [126] 0 0
Japan
State/province [126] 0 0
Hatsukaichi-shi, Hiroshima
Country [127] 0 0
Japan
State/province [127] 0 0
Hiroshima-shi, Hiroshima
Country [128] 0 0
Japan
State/province [128] 0 0
Izunokuni-shi, Shizuoka
Country [129] 0 0
Japan
State/province [129] 0 0
Kagoshima-shi, Kagoshima
Country [130] 0 0
Japan
State/province [130] 0 0
Kamigyo-ku, Kyoto
Country [131] 0 0
Japan
State/province [131] 0 0
Kanazawa-shi, Ishikawa
Country [132] 0 0
Japan
State/province [132] 0 0
Kashihara-shi, Nara
Country [133] 0 0
Japan
State/province [133] 0 0
Kawasaki-shi, Kanagawa
Country [134] 0 0
Japan
State/province [134] 0 0
Kumamoto-shi, Kumamoto
Country [135] 0 0
Japan
State/province [135] 0 0
Minato-ku, Tokyo
Country [136] 0 0
Japan
State/province [136] 0 0
Musashino-shi, Tokyo
Country [137] 0 0
Japan
State/province [137] 0 0
Nagakute-shi, Aichi
Country [138] 0 0
Japan
State/province [138] 0 0
Nakagamigun, Okinawa
Country [139] 0 0
Japan
State/province [139] 0 0
Nara-shi, Nara
Country [140] 0 0
Japan
State/province [140] 0 0
Nishinomiya-shi, Hyogo
Country [141] 0 0
Japan
State/province [141] 0 0
Oita-shi, Oita
Country [142] 0 0
Japan
State/province [142] 0 0
Okayama-shi, Okayama
Country [143] 0 0
Japan
State/province [143] 0 0
Osaka-shi, Osaka
Country [144] 0 0
Japan
State/province [144] 0 0
Osaka
Country [145] 0 0
Japan
State/province [145] 0 0
Otsu-shi, Shiga
Country [146] 0 0
Japan
State/province [146] 0 0
Saga-shi, Saga
Country [147] 0 0
Japan
State/province [147] 0 0
Sapporo-shi, Hokkaido
Country [148] 0 0
Japan
State/province [148] 0 0
Sendai-shi, Miyagi
Country [149] 0 0
Japan
State/province [149] 0 0
Shinjuku-ku, Tokyo
Country [150] 0 0
Japan
State/province [150] 0 0
Suita-shi, Osaka
Country [151] 0 0
Japan
State/province [151] 0 0
Takamatsu-shi, Kagawa
Country [152] 0 0
Japan
State/province [152] 0 0
Takasaki-shi, Gunma
Country [153] 0 0
Japan
State/province [153] 0 0
Tokyo
Country [154] 0 0
Japan
State/province [154] 0 0
Toon-shi, Ehime
Country [155] 0 0
Japan
State/province [155] 0 0
Wakayama-shi, Wakayama
Country [156] 0 0
Japan
State/province [156] 0 0
Yokohama-shi, Kanagawa
Country [157] 0 0
Korea, Republic of
State/province [157] 0 0
Daegu
Country [158] 0 0
Korea, Republic of
State/province [158] 0 0
Gangwon-do
Country [159] 0 0
Korea, Republic of
State/province [159] 0 0
Gyeonggi-do
Country [160] 0 0
Korea, Republic of
State/province [160] 0 0
Seoul
Country [161] 0 0
Malaysia
State/province [161] 0 0
Kelantan
Country [162] 0 0
Malaysia
State/province [162] 0 0
Wilayah Persekutuan Kuala Lumpur
Country [163] 0 0
Malaysia
State/province [163] 0 0
Batu Caves
Country [164] 0 0
Mexico
State/province [164] 0 0
Guerrero
Country [165] 0 0
Mexico
State/province [165] 0 0
Jalisco
Country [166] 0 0
Mexico
State/province [166] 0 0
México, D.F.
Country [167] 0 0
Mexico
State/province [167] 0 0
Nuevo Leon
Country [168] 0 0
Mexico
State/province [168] 0 0
Nuevo León
Country [169] 0 0
Mexico
State/province [169] 0 0
Sinaloa
Country [170] 0 0
Mexico
State/province [170] 0 0
Yucatan
Country [171] 0 0
Mexico
State/province [171] 0 0
Mexico
Country [172] 0 0
Netherlands
State/province [172] 0 0
Alkmaar
Country [173] 0 0
Netherlands
State/province [173] 0 0
Amsterdam
Country [174] 0 0
Netherlands
State/province [174] 0 0
Leiden
Country [175] 0 0
Netherlands
State/province [175] 0 0
Rotterdam
Country [176] 0 0
Norway
State/province [176] 0 0
Gjettum
Country [177] 0 0
Norway
State/province [177] 0 0
Oslo
Country [178] 0 0
Poland
State/province [178] 0 0
Malopolskie
Country [179] 0 0
Poland
State/province [179] 0 0
Bydgoszcz
Country [180] 0 0
Poland
State/province [180] 0 0
Staszow
Country [181] 0 0
Poland
State/province [181] 0 0
Warszawa
Country [182] 0 0
Poland
State/province [182] 0 0
Wroclaw
Country [183] 0 0
Poland
State/province [183] 0 0
Swietokrzyskie
Country [184] 0 0
Portugal
State/province [184] 0 0
Matosinhos
Country [185] 0 0
Portugal
State/province [185] 0 0
Almada
Country [186] 0 0
Portugal
State/province [186] 0 0
Aveiro
Country [187] 0 0
Portugal
State/province [187] 0 0
Braga
Country [188] 0 0
Portugal
State/province [188] 0 0
Guarda
Country [189] 0 0
Portugal
State/province [189] 0 0
Guimarães
Country [190] 0 0
Portugal
State/province [190] 0 0
Lisboa
Country [191] 0 0
Portugal
State/province [191] 0 0
Porto
Country [192] 0 0
Portugal
State/province [192] 0 0
Viana do Castelo
Country [193] 0 0
Portugal
State/province [193] 0 0
Vila Nova de Gaia
Country [194] 0 0
Portugal
State/province [194] 0 0
Vila Real
Country [195] 0 0
Puerto Rico
State/province [195] 0 0
San Juan
Country [196] 0 0
Romania
State/province [196] 0 0
Bucharest
Country [197] 0 0
Romania
State/province [197] 0 0
Bucuresti
Country [198] 0 0
Romania
State/province [198] 0 0
Cluj-Napoca
Country [199] 0 0
Romania
State/province [199] 0 0
Constanta
Country [200] 0 0
Romania
State/province [200] 0 0
Galati
Country [201] 0 0
Romania
State/province [201] 0 0
Iasi
Country [202] 0 0
Romania
State/province [202] 0 0
Satu Mare
Country [203] 0 0
Russian Federation
State/province [203] 0 0
Arkhangelsk
Country [204] 0 0
Russian Federation
State/province [204] 0 0
Kazan
Country [205] 0 0
Russian Federation
State/province [205] 0 0
Moscow
Country [206] 0 0
Russian Federation
State/province [206] 0 0
Novosibirsk
Country [207] 0 0
Russian Federation
State/province [207] 0 0
Saint Petersburg
Country [208] 0 0
Russian Federation
State/province [208] 0 0
Saint-Petersburg
Country [209] 0 0
Russian Federation
State/province [209] 0 0
Ulianovsk
Country [210] 0 0
Russian Federation
State/province [210] 0 0
Yoshkar-Ola
Country [211] 0 0
Serbia
State/province [211] 0 0
Vojvodina
Country [212] 0 0
Serbia
State/province [212] 0 0
Belgrade
Country [213] 0 0
Singapore
State/province [213] 0 0
Singapore
Country [214] 0 0
Slovakia
State/province [214] 0 0
Bratislava
Country [215] 0 0
Slovakia
State/province [215] 0 0
Kosice
Country [216] 0 0
Slovakia
State/province [216] 0 0
Michalovce
Country [217] 0 0
Slovakia
State/province [217] 0 0
Trnava
Country [218] 0 0
South Africa
State/province [218] 0 0
Eastern Cape
Country [219] 0 0
South Africa
State/province [219] 0 0
Gauteng
Country [220] 0 0
South Africa
State/province [220] 0 0
KwaZulu-Natal
Country [221] 0 0
South Africa
State/province [221] 0 0
Western Cape
Country [222] 0 0
South Africa
State/province [222] 0 0
Johannesburg
Country [223] 0 0
Spain
State/province [223] 0 0
Galicia
Country [224] 0 0
Spain
State/province [224] 0 0
Barcelona
Country [225] 0 0
Spain
State/province [225] 0 0
Majadahonda
Country [226] 0 0
Spain
State/province [226] 0 0
Pontevedra
Country [227] 0 0
Spain
State/province [227] 0 0
Santander
Country [228] 0 0
Spain
State/province [228] 0 0
Sevilla
Country [229] 0 0
Spain
State/province [229] 0 0
Valencia
Country [230] 0 0
Spain
State/province [230] 0 0
Valladolid
Country [231] 0 0
Switzerland
State/province [231] 0 0
Bern
Country [232] 0 0
Switzerland
State/province [232] 0 0
Geneva
Country [233] 0 0
Switzerland
State/province [233] 0 0
Olten
Country [234] 0 0
Switzerland
State/province [234] 0 0
St. Gallen
Country [235] 0 0
Taiwan
State/province [235] 0 0
Chiayi City
Country [236] 0 0
Taiwan
State/province [236] 0 0
Kaohsiung
Country [237] 0 0
Taiwan
State/province [237] 0 0
New Taipei City
Country [238] 0 0
Taiwan
State/province [238] 0 0
Taichung
Country [239] 0 0
Taiwan
State/province [239] 0 0
Tainan City
Country [240] 0 0
Taiwan
State/province [240] 0 0
Taipei city
Country [241] 0 0
Taiwan
State/province [241] 0 0
Taipei
Country [242] 0 0
Turkey
State/province [242] 0 0
Adana
Country [243] 0 0
Turkey
State/province [243] 0 0
Ankara
Country [244] 0 0
Turkey
State/province [244] 0 0
Bursa
Country [245] 0 0
Turkey
State/province [245] 0 0
Istanbul
Country [246] 0 0
Turkey
State/province [246] 0 0
Izmir
Country [247] 0 0
Turkey
State/province [247] 0 0
Kocaeli
Country [248] 0 0
Turkey
State/province [248] 0 0
Mersin
Country [249] 0 0
United Kingdom
State/province [249] 0 0
Birmingham
Country [250] 0 0
United Kingdom
State/province [250] 0 0
Derby
Country [251] 0 0
United Kingdom
State/province [251] 0 0
Dundee
Country [252] 0 0
United Kingdom
State/province [252] 0 0
Exeter
Country [253] 0 0
United Kingdom
State/province [253] 0 0
Hull
Country [254] 0 0
United Kingdom
State/province [254] 0 0
Ipswich
Country [255] 0 0
United Kingdom
State/province [255] 0 0
Leeds
Country [256] 0 0
United Kingdom
State/province [256] 0 0
London
Country [257] 0 0
United Kingdom
State/province [257] 0 0
Newcastle upon Tyne
Country [258] 0 0
United Kingdom
State/province [258] 0 0
Newcastle-Upon Tyne
Country [259] 0 0
United Kingdom
State/province [259] 0 0
Nottingham
Country [260] 0 0
United Kingdom
State/province [260] 0 0
Oxford
Country [261] 0 0
United Kingdom
State/province [261] 0 0
Plymouth
Country [262] 0 0
United Kingdom
State/province [262] 0 0
Southampton
Country [263] 0 0
United Kingdom
State/province [263] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novo Nordisk A/S
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries.

Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance.

Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week.

The study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day.

Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
Trial website
https://clinicaltrials.gov/study/NCT04822181
Trial related presentations / publications
Newsome PN, Sanyal AJ, Engebretsen KA, Kliers I, Ostergaard L, Vanni D, Bugianesi E, Rinella ME, Roden M, Ratziu V. Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024 Oct 16. doi: 10.1111/apt.18331. Online ahead of print.
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Transparency (dept. 2834)
Address 0 0
Novo Nordisk A/S
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Novo Nordisk
Address 0 0
Country 0 0
Phone 0 0
(+1) 866-867-7178
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04822181